North America Injectable Drug Delivery Market - Industry Trends and Forecast to 2024

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email
US : +1-888-387-2818
UK : +44-161-394-0625
Want create site? Find Free WordPress Themes and plugins.

North America Injectable Drug Delivery Market – Industry Trends and Forecast to 2024

North America
Publish Reports
North America Injectable Drug Delivery Market
  • No of pages :
    150
  • No of Figures:
    50
  • No of Tables:
    250
  • Report Type:
    Publish

North America Injectable Drug Delivery Market – By Type {Devices (Conventional, Self), Formulations (Conventional, Noble, Long Acting)} Applications (Autoimmune Diseases, Hormonal Disorders, Others) Usage Pattern (Curative Care, Immunizations, Other Usage Patterns) Mode of Administration (Skin, Circulatory, Organs, Central Nervous System) End User (Hospitals, Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies) Country (U.S., Canada, Mexico) – Industry Trends and Forecast to 2024

Want create site? Find Free WordPress Themes and plugins.

North America Injectable Drug Delivery Market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.North America Injectable Drug Delivery Market

North America Injectable Drug Delivery Market is segmented on the basis of type, applications, usage pattern, mode of administration, end user, and country.

Based on type, the injectable drug delivery market is segmented into devices and formulations.

By product, the needle free injectors are further segmented into fillable needle-free injectors and prefilled needle-free injectors. 

By usability, the needle free injector is segmented into disposable and reusable injectors.

By design, the auto injectors is segmented into standardized and customizable autoinjectors. 

On the basis of applications, the  injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.

Based on indications, the market is segmented into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis, and others.

On the basis of usage pattern, the market is segmented into curative care, immunization, and others.

Based on mode of administration, the market is segmented into skin, circulatory, organs, and central nervous system.

On the basis of end user, the North America injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories, and pharma and biotech companies. 

Based on country, the market is segmented into U.S, Canada, and Mexico.

The report also includes company’s share analysis for the major companies operating in this market by major regions of North America.

Some of the major players operating in the Injectable drug delivery market are Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, and Teva Pharmaceuticals Industries Ltd., among others.

Did you find apk for android? You can find new Free Android Games and apps.
Choose Licence Type

Enterprise, Single User

Want create site? Find Free WordPress Themes and plugins.

1. INTRODUCTION

       1.1. OVERVIEW OF THE NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
       1.2. MARKET SEGMENTATION & COVERAGE
                1.2.1. CURRENCY AND PRICING
                1.2.2. LIMITATION
                1.2.3. STAKEHOLDERS

2. RESEARCH METHODOLOGY

       2.1. KEY TAKEAWAYS
       2.2. ARRIVING AT THE NORTH AMERICA  INJECTABLE DRUG DELIVERY MARKET SIZE
                2.2.1. MARKET CRACKDOWN APPROACH
                2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
                2.2.3. DATA TRIANGULATION
                2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
                2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
                2.2.6. PORTER’S FIVE FORCES MATRIX
       2.3.NORTH AMERICA  INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
       2.4. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

       4.1. OVERVIEW
       4.2.NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
       4.3. MARKET OVERVIEW
                4.3.1. DRIVERS
                           4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
                           4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
                           4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
                           4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
                4.3.2. RESTRAINTS
                4.3.3. OPPORTUNITIES
                           4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES
                4.3.4. THREATS
                           4.3.4.1. PRODUCT RECALLS
                           4.3.4.2. REGULATORY HURDLES
                           4.3.4.3. STABILITY OF PRODUCTS
                           4.3.4.4. STERILITY OF INJECTIONS
                           4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES
       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5.NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY TYPE

       5.1. OVERVIEW
       5.2. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES
       5.3.NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS

6.NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

       6.1. OVERVIEW
       6.2. CONVENTIONAL INJECTION DEVICES
                6.2.1. BY MATERIAL
                           6.2.1.1. GLASS
                           6.2.1.2. PLASTIC
                6.2.2. BY PRODUCT
                           6.2.2.1. EMPTY SYRINGES
                           6.2.2.2. PREFILLED SYRINGES
                6.2.3. BY USABLITY
                           6.2.3.1. REUSABLE SYRINGES
                           6.2.3.2. DISPOSABLE SYRINGES
       6.3. SELF INJECTION DEVICES
                6.3.1. NEEDLE FREE INJECTORS
                           6.3.1.1. BY PRODUCT
                                         6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
                                         6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS
                            6.3.1.2. BY TECHNOLOGY
                                         6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
                                         6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
                                         6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
                                         6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
                           6.3.1.3. BY USABILITY
                                         6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
                                         6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
                6.3.2. AUTOINJECTORS
                           6.3.2.1. BY PRODUCT
                                         6.3.2.1.1. EMPTY AUTOINJECTORS
                                         6.3.2.1.2. PREFILLED AUTOINJECTORS
                           6.3.2.2. BY TECHNOLOGY
                                         6.3.2.2.1. AUTOMATED AUTOINJECTORS
                                         6.3.2.2.2. MANUAL AUTOINJECTORS
                           6.3.2.3. BY DESIGN
                                         6.3.2.3.1. STANDARDIZED AUTOINJECTORS
                                         6.3.2.3.2. CUSTOMIZED AUTOINJECTORS
                           6.3.2.4. BY USABILITY
                                         6.3.2.4.1. REUSABLE AUTOINJECTORS
                                         6.3.2.4.2. DISPOSABLE AUTOINJECTORS
                6.3.3. PEN INJECTORS
                           6.3.3.1. BY PRODUCT
                                         6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
                                         6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS
                           6.3.3.2. BY DESIGN
                                         6.3.3.2.1. STANDARDIZED PEN INJECTORS
                                         6.3.3.2.2. CUSTOMIZED PEN INJECTORS
                           6.3.3.3. BY USABILITY
                                         6.3.2.3.1. REUSABLE PEN INJECTORS
                                         6.3.2.3.2. DISPOSABLE PEN INJECTORS
                6.3.4. WEARABLE INJECTORS
                6.3.5. OTHER INJECTABLE DEVICES

7.  NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE

       7.1. OVERVIEW
       7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
                7.2.1. SOLUTIONS
                7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
                7.2.3. SUSPENSIONS
                7.2.4. EMULSIONS
       7.3. NOVEL DRUG DELIVERY FORMULATIONS
                7.3.1. COLLOIDAL DISPERSIONS
                           7.3.1.1. LIPOSOMES
                           7.3.1.2. NIOSOMES
                           7.3.1.3. POLYMERIC MIXED MICELLES
                           7.3.1.4. NANOPARICLES
                                         7.3.1.4.1. NANOSUSPENSIONS
                                         7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS
                                         7.3.1.4.3. SOLID LIPID NANOPARTICLES
                7.3.2. MICROPARTICLES
                           7.3.2.1. MICROSPHERES
                           7.3.2.2. MICROCAPSULES
                7.3.3. LONG ACTING INJECTION FORMULATIONS

8.NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS

       8.1. OVERVIEW
       8.2. AUTOIMMUNE DISEASES
                8.2.1. RHEUMATOID ARTHRITIS
                8.2.2. MULTIPLE SCLEROSIS
                8.2.3. CHRON’S DISEASE
                8.2.4. PSORIASIS
                8.2.5. OTHER AUTOIMMUNE DISEASES
       8.3. HORMONAL DISORDERS
                8.3.1. DIABETES
                8.3.2. ANEMIA
                8.3.3. REPRODUCTIVE HEALTH DISEASE
                8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
                8.3.5. OSTEOPOROSIS
                8.3.6. GROWTH HORMONE DEFICIENCY (GHD)
       8.4. ORPHAN DISEASES
       8.5. ONCOLOGY
       8.6. OTHERS
                8.6.1. PAIN MANAGEMENT
                8.6.2. ALERGY TREATMENT
                8.6.3. AESTHETIC TREATMENTS
                8.6.4. HEPATITIS C
                8.6.5. HEMOPHILIA

9. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

       9.1. OVERVIEW
       9.2. CURATIVE CARE
       9.3. IMMUNIZATIONS
       9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)

10. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

       10.1. OVERVIEW
       10.2. SKIN
       10.3. CIRCULATORY/MUSKOSKELETAL
       10.4. ORGANS
       10.5. CENTRAL NERVOUS SYSTEM

11. INJECTABLE DRUG DELIVERY MARKET, BY END USER

       11.1. OVERVIEW
       11.2. HOSPITALS AND CLINICS
       11.3. HOME HEALTHCARE SETTINGS
       11.4. RESEARCH LABORATORIES
       11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
       11.6. OTHER END USERS

12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

       12.1. COUNTRYWISE  INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
                12.1.1. NORTH AMERICA
                                         12.1.1.1. U.S.
                                         12.1.1.2. CANADA
                                          12.1.1.3. MEXICO
       12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

13. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE

       13.1.NORTH AMERICA  INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
       13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
       13.3. CANADA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
       13.4. MAXICO INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES

       14.1. BAXTER INTERNATIONAL, INC.
                14.1.1. OVERVIEW
                14.1.2. SWOT ANALYSIS
                14.1.3. PRODUCT PORTFOLIO
                14.1.4. REVENUE ANALYSIS
                14.1.5. ANALYSTS VIEW
       14.2. BECTON, DICKINSON AND COMPANY
                14.2.1. OVERVIEW
                14.2.2. SWOT ANALYSIS
                14.2.3. PRODUCT PORTFOLIO
                14.2.4. REVENUE ANALYSIS
                14.2.5. ANALYSTS VIEW
       14.3. GERRESHEIMER, AG
                14.3.1. OVERVIEW
                14.3.2. SWOT ANALYSIS
                14.3.3. PRODUCT PORTFOLIO
                14.3.4. REVENUE ANALYSIS
                14.3.5. ANALYST VIEW
       14.4. PFIZER, INC.
                14.4.1. OVERVIEW
                14.4.2. SWOT ANALYSIS
                14.4.3. PRODUCT PORTFOLIO
                14.4.4. REVENUE ANALYSIS
                14.4.5. ANALYSTS VIEW
       14.5. SCHOTT AG
                14.5.1. OVERVIEW
                14.5.2. SWOT ANALYSIS
                14.5.3. PRODUCT PORTFOLIO
                14.5.4. REVENUE ANALYSIS
                14.5.5. ANALYSTS VIEW
       14.6. ALKERMES PLC
                14.6.1. OVERVIEW
                14.6.2. SWOT ANALYSIS
                14.6.3. PRODUCT PORTFOLIO
                14.6.4. REVENUE ANALYSIS
                14.6.5. ANALYSTS VIEW
       14.7. ELI LILLY AND COMPANY
                14.7.1. OVERVIEW
                14.7.2. SWOT ANALYSIS
                14.7.3. PRODUCT PORTFOLIO
                14.7.4. REVENUE ANALYSIS
                14.7.5. ANALYSTS VIEW
       14.8. SANDOZ
                14.8.1. OVERVIEW
                14.8.2. SWOT ANALYSIS
                14.8.3. PRODUCT PORTFOLIO
                14.8.4. REVENUE ANALYSIS
                14.8.5. ANALYSTS VIEW
       14.9. TERUMO CORPORATION
                14.9.1. OVERVIEW
                14.9.2. SWOT ANALYSIS
                14.9.3. PRODUCT PORTFOLIO
                14.9.4. REVENUE ANALYSIS
                14.9.5. ANALYSTS VIEW
       14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
                14.10.1. OVERVIEW
                14.10.2. SWOT ANALYSIS
                14.10.3. PRODUCT PORTFOLIO
                14.10.4. REVENUE ANALYSIS
                14.10.5. ANALYSTS VIEW

15. APPENDIX

       15.1. RELATED REPORTS
       15.2. CUSTOMIZABLE OPTIONS
       15.3. SOURCE SHEET
       15.4. BIBLIOGRAPHY

16. ABOUT DATA BRIDGE MARKET RESEARCH

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Available on Request.

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Available on Request.

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Please fill in the below form and our sales representatives will get back to you.

Thank You

Did you find apk for android? You can find new Free Android Games and apps.
Want create site? Find Free WordPress Themes and plugins.

Thank You

Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.
`